Kidney Disease News and Research

RSS

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

Scientists combine two agents to treat patients with multiple myeloma

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data showing that by combining two treatment agents in the care of multiple myeloma patients, doctors can use higher dosages of chemotherapy before autologous stem cell transplant while alleviating painful and debilitating side effects like severe oral mucositis (mouth ulcers).

8 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

Researcher calls stroke specialists to further knowledge and understanding of stroke

To cope with the projected growth in the incidence of strokes in Canada, the public may need to take on roles traditionally performed by healthcare specialists, according to a leading Canadian stroke researcher.

7 Jun 2010

Positive results from new analyses of denosumab Phase 3 trials

Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

DaVita receives subpoena from Department of Health and Human Services OIG

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.

4 Jun 2010

Kidney dialysis patients unprepared for disasters: Study

Immediately after Hurricane Katrina in August 2005, the survival of more than 5,800 Gulf Coast kidney dialysis patients was threatened as the storm forced closure of 94 dialysis units. Within a month 148 of these patients had died.

4 Jun 2010

Growth hormone treatment promotes growth in infants with CRF: Study

Infants with chronic renal failure grow slowly, a problem that usually improves with aggressive nutritional therapy. When it doesn't, growth hormone is a safe and effective treatment to promote growth, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

4 Jun 2010

Over-the-counter supplements can cause hypertension and kidney failure

Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Results of a subanalysis from the FAIR-HF study demonstrate that correcting iron deficiency with Ferinject (ferric carboxymaltose) can improve renal function in chronic heart failure patients. Ferinject is an intravenous iron product used to treat iron deficiency and iron deficiency anaemia.

From CSL Ltd 31 May 2010

Researchers identify gene responsible for Meckel-Gruber and Joubert syndromes

An international group of researchers has identified the genetic cause of an inherited condition that causes severe foetal abnormalities.

31 May 2010

MU awarded $6.8M to help patients benefit from use of health information technology

Considered one the great advances of modern medicine, electronic health records can provide a patient's entire medical history and a wealth of other information at the click of a button. They also have the potential to save countless lives and billions of dollars. Now, the University of Missouri has a two-year, $6.8 million cooperative agreement to help patients throughout the state benefit from increased use of this health information technology.

29 May 2010

DaVita provides hurricane hotline to help dialysis patients find clinics, schedule treatments during emergencies

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, announced today that the company will provide a hurricane hotline (1-800-400-8331) that is activated 24 hours a day, seven days a week to help dialysis patients find open clinics and schedule treatments during emergencies such as hurricanes and other natural disasters.

28 May 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.

28 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

BTE awards Diabetes Care Recognition Program certificates to 118 Montefiore Medical Group physicians

Bridges to Excellence, a national program that recognizes and rewards physicians for delivering better quality care, today awarded its sought-after Diabetes Care Recognition Program certificate to the 118 physicians in Montefiore Medical Center's 20 outpatient care facilities, known as the Montefiore Medical Group, for substantially lowering blood sugar levels and "bad" cholesterol levels in thousands of adult patients with diabetes.

28 May 2010

Kidney Disease News and Research

Pharnext closes €4.8-million Series A funding round

Scientists combine two agents to treat patients with multiple myeloma

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Researcher calls stroke specialists to further knowledge and understanding of stroke

Positive results from new analyses of denosumab Phase 3 trials

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

DaVita receives subpoena from Department of Health and Human Services OIG

Kidney dialysis patients unprepared for disasters: Study

Growth hormone treatment promotes growth in infants with CRF: Study

Over-the-counter supplements can cause hypertension and kidney failure

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency

Researchers identify gene responsible for Meckel-Gruber and Joubert syndromes

MU awarded $6.8M to help patients benefit from use of health information technology

DaVita provides hurricane hotline to help dialysis patients find clinics, schedule treatments during emergencies

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Amgen announces European approval of Prolia

BTE awards Diabetes Care Recognition Program certificates to 118 Montefiore Medical Group physicians

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News